Clinical Pharmacist University of Utah Hospitals and Clinics Salt Lake City, Utah
The ongoing launch of biosimilars for autoimmune disease will continue to lower the cost of these types of specialty medications. For example, multiple adalimumab biosimilars are expected to hit the US market this year, there are ustekinumab biosimilars under FDA review, and biosimilars for other anti-inflammatory drugs are currently in development. This session will highlight what’s new in autoimmune specialty pharmacy, with a focus on meds used to treat conditions in the therapeutic areas of gastroenterology and rheumatology.